The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
“Is dopamine involved in Alzheimer's disease?â€
Open accessAbstract
Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and dementia. Recent advances indicate that AD pathogenesis appears more complex than its mere neuropathology. Changes in synaptic plasticity, neuronal disarray and cell death are pathways commonly recognized as pathogenic mechanisms of AD. It is thought that the altered metabolism of certain membrane proteins may lead to the production of amyloid (Aβ) oligomers that are characterized by an highly toxic effect on neurotransmission pathways, such as those mediated by Acetylcholine. The interaction of Aβ oligomers with these neurotansmitters systems would in turn induce cell dysfunction, neurotransmitters signaling imbalance and finally lead to the appearance of neurological signs. In this perspective, it is still debated how and if these mechanisms may also engage the dopaminergic system in AD. Recent experimental work revealed that the dopaminergic system may well be involved in the occurrence of cognitive decline, often being predictive of rapidly progressive forms of AD. However, a clear idea on the role of the dopamine system in AD is still missing. Here we review the more recent evidences supporting the notion that the dopaminergic dysfunction has a pathogenic role in cognitive decline symptoms of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The reward circuit: linking primate anatomy and human imaging
Haber, S. N., & Knutson, B. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.129 · Cited by 3,718
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651
Depp, C. A., & Jeste, D. V. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192501.03069.bc · Cited by 1,292
The cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876
β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity
Wang, H.-Y., Lee, D. H. S., D'Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 822
Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli
Lammel, S., Ion, D. I., Roeper, J., & Malenka, R. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.03.025 · Cited by 766
Turner, P. R., O’Connor, K., Tate, W. P., & Abraham, W. C. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00089-3 · Cited by 756
Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus
Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., & Arancio, O. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2692-08.2008 · Cited by 740
Functional Alterations in Memory Networks in Early Alzheimer’s Disease
Sperling, R. A., Dickerson, B. C., Pihlajamaki, M., Vannini, P., LaViolette, P. S., Vitolo, O. V., Hedden, T., Becker, J. A., Rentz, D. M., Selkoe, D. J., et al. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8109-7 · Cited by 604
Living on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436
Bäckman, L., Lindenberger, U., Li, S.-C., & Nyberg, L. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.12.008 · Cited by 414
Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease
Kar, S., Slowikowski, S. P. M., Westaway, D., & Mount, H. T. J. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0442 · Cited by 364
Amyloid‐β associated cortical thinning in clinically normal elderly
Becker, J. A., Hedden, T., Carmasin, J., Maye, J., Rentz, D. M., Putcha, D., Fischl, B., Greve, D. N., Marshall, G. A., Salloway, S., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22333 · Cited by 342
The amyloid precursor protein: A biochemical enigma in brain development, function and disease
Nalivaeva, N. N., & Turner, A. J. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.010 · Cited by 273
Lewy body-related ?-synucleinopathy in the aged human brain
Jellinger, K. A. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0138-7 · Cited by 256
Grinberg, L. T., Rüb, U., Ferretti, R. E. L., Nitrini, R., Farfel, J. M., Polichiso, L., Gierga, K., Jacob‐Filho, W., Heinsen, H., & Brazilian Brain Bank Study Group (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00997.x · Cited by 241
The Primate Substantia Nigra and VTA: Integrative Circuitry and Function
Haber, S. N., & Fudge, J. L. (1997) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v11.i4.40 · Cited by 226
CSF biomarkers predict a more malignant outcome in Alzheimer disease
Wallin, A. K., Blennow, K., Zetterberg, H., Londos, E., Minthon, L., & Hansson, O. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dd4dd8 · Cited by 223
Trillo, L., Das, D., Hsieh, W., Medina, B., Moghadam, S., Lin, B., Dang, V., Sanchez, M. M., De Miguel, Z., Ashford, J. W., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.008 · Cited by 221
Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients
Storga, D., Vrecko, K., Birkmayer, J. G. D., & Reibnegger, G. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12256-7 · Cited by 208
Decreased dopamine transporters with age in healthy human subjects
Volkow, N. D., Fowler, J. S., Wang, G. J., Logan, J., Schlyer, D., MacGregor, R., Hitzemann, R., & Wolf, A. P. (1994) · Annals of Neurology · doi:10.1002/ana.410360218 · Cited by 205
Does Alzheimer's disease begin in the brainstem?
Simic, G., Stanic, G., Mladinov, M., Jovanov‐Milosevic, N., Kostovic, I., & Hof, P. R. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01038.x · Cited by 204
Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?
Esposito, Z., Belli, L., Toniolo, S., Sancesario, G., Bianconi, C., & Martorana, A. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12095 · Cited by 196
Self-citationRapidly Progressive Alzheimer Disease
Schmidt, C., Wolff, M., Weitz, M., Bartlau, T., Korth, C., & Zerr, I. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.189 · Cited by 193
Comparison of 18F-FDG and PiB PET in Cognitive Impairment
Lowe, V. J., Kemp, B. J., Jack, C. R., Senjem, M., Weigand, S., Shiung, M., Smith, G., Knopman, D., Boeve, B., Mullan, B., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058529 · Cited by 192
Formation and development of Lewy pathology: a critical update
Jellinger, K. A. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5243-y · Cited by 190
Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes.
Braak, H., & Braak, E. (1990) · PubMed · Cited by 189
Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias
Colloby, S. J., McParland, S., O'Brien, J. T., & Attems, J. (2012) · Brain · doi:10.1093/brain/aws211 · Cited by 188
The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs
Burns, J. M., Galvin, J. E., Roe, C. M., Morris, J. C., & McKeel, D. W. (2005) · Neurology · doi:10.1212/01.wnl.0000158423.05224.7f · Cited by 176
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
Alzheimerʼs Disease: Striatal Amyloid Deposits and Neurofibrillary Changes
BRAAK, H., & BRAAK, E. (1990) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199005000-00003 · Cited by 173
Apomorphine treatment in Alzheimer mice promoting amyloid‐β degradation
Himeno, E., Ohyagi, Y., Ma, L., Nakamura, N., Miyoshi, K., Sakae, N., Motomura, K., Soejima, N., Yamasaki, R., Hashimoto, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22319 · Cited by 170
Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease
Kemppainen, N., Laine, M., Laakso, M. P., Kaasinen, V., Någren, K., Vahlberg, T., Kurki, T., & Rinne, J. O. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02716.x · Cited by 165
Amyloid-β Peptide: Dr. Jekyll or Mr. Hyde?
Puzzo, D., & Arancio, O. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129033 · Cited by 164
Dopaminergic Modulation of Cortical Plasticity in Alzheimer’s Disease Patients
Koch, G., Lorenzo, F. D., Bonnì, S., Giacobbe, V., Bozzali, M., Caltagirone, C., & Martorana, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.119 · Cited by 158
Self-citationThe Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease
Mitchell, R. A., Herrmann, N., & Lanctôt, K. L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00161.x · Cited by 153
Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer's Disease Patients
Martorana, A., Mori, F., Esposito, Z., Kusayanagi, H., Monteleone, F., Codecà, C., Sancesario, G., Bernardi, G., & Koch, G. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.60 · Cited by 150
Self-citationRudelli, R. D., Ambler, M. W., & Wísniewski, H. M. (1984) · Acta Neuropathologica · doi:10.1007/bf00690393 · Cited by 136
Murray, A. M., Weihmueller, F. B., Marshall, J. F., Hurtig, H. I., Gottleib, G. L., & Joyce, J. N. (1995) · Annals of Neurology · doi:10.1002/ana.410370306 · Cited by 135
Extrapyramidal Signs in Patients With Probable Alzheimer Disease
López, O. L., Wisnieski, S. R., Becker, J. T., Boiler, F., & DeKosky, S. T. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550200033007 · Cited by 133
Nicotinic Receptors in Neurodegeneration
Posadas, I., López‐Hernández, B., & Ceña, V. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030005 · Cited by 132
Guzmán-Ramos, K., Moreno-Castilla, P., Castro-Cruz, M., McGaugh, J. L., Martínez-Coria, H., LaFerla, F. M., & Bermúdez-Rattoni, F. (2012) · Learning & Memory · doi:10.1101/lm.026070.112 · Cited by 127
Kumar, U., & Patel, S. C. (2006) · Brain Research · doi:10.1016/j.brainres.2006.10.049 · Cited by 125
Richard, E., Schmand, B. A., Eikelenboom, P., Yang, S., Ligthart, S. A., van Charante, E. P. M., & van Gool, W. A. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000338239 · Cited by 123
The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome
Gibb, W. R., Mountjoy, C. Q., Mann, D. M., & Lees, A. J. (1989) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.2.193 · Cited by 122
CSF biomarkers in relationship to cognitive profiles in Alzheimer disease
van der Vlies, A. E., Verwey, N. A., Bouwman, F. H., Blankenstein, M. A., Klein, M., Scheltens, P., & van der Flier, W. M. (2009) · Neurology · doi:10.1212/01.wnl.0000345014.48839.71 · Cited by 118
Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer’s disease
Ambrée, O., Richter, H., Sachser, N., Lewejohann, L., Dere, E., de Souza Silva, M. A., Herring, A., Keyvani, K., Paulus, W., & Schäbitz, W.-R. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.010 · Cited by 115
Joyce, J. N., Smutzer, G., Whitty, C. J., Myers, A., & Bannon, M. J. (1997) · Movement Disorders · doi:10.1002/mds.870120609 · Cited by 113
Martorana, A., Lorenzo, F. D., Esposito, Z., Giudice, T. L., Bernardi, G., Caltagirone, C., & Koch, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.015 · Cited by 96
Self-citationFranch, J. V., Calvó‐Perxas, L., Garre‐Olmo, J., Garriga, O. T., & Pousa, S. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120913 · Cited by 92
Nigrostriatal Dysfunction in Familial Alzheimer's Disease-Linked APPswe/PS1ΔE9 Transgenic Mice
Perez, S. E., Lazarov, O., Koprich, J. B., Chen, E., Rodriguez‐Menendez, V., Lipton, J. W., Sisodia, S. S., & Mufson, E. J. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2773-05.2005 · Cited by 92
Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs
Attems, J., Quass, M., & Jellinger, K. A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0146-9 · Cited by 90
REVIEW: Apathy Diagnosis, Assessment, and Treatment in Alzheimer's Disease
Robert, P. H., Mulin, E., Malléa, P., & David, R. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00132.x · Cited by 89
Ni, R., Marutle, A., & Nordberg, A. K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121447 · Cited by 85
Portet, F., Scarmeas, N., Cosentino, S., Helzner, E. P., & Stern, Y. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.196 · Cited by 79
The relationship between subcortical tau pathology and Alzheimer's disease
Attems, J., Thal, D. R., & Jellinger, K. A. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120034 · Cited by 76
Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach
Iqbal, K., del Alonso, A. C., Gondal, J. A., Gong, C., Haque, N., Khatoon, S., Sengupta, A., Wang, J.-Z., & Grundke, I. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_22 · Cited by 68
Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study
Pievani, M., Bocchetta, M., Boccardi, M., Cavedo, E., Bonetti, M., Thompson, P. M., & Frisoni, G. B. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.01.016 · Cited by 67
A Non-α7 Nicotinic Acetylcholine Receptor Modulates Excitatory Input to Hippocampal CA1 Interneurons
Alkondon, M., & Albuquerque, E. X. (2002) · Journal of Neurophysiology · doi:10.1152/jn.00708.2001 · Cited by 67
Loss of Dopamine Uptake Sites Labeled with [ 3 H]GBR-12935 in Alzheimer’s Disease
Allard, P., Alafuzoff, I., Carlsson, A., Eriksson, K., Ericson, E., Gottfries, C.-G., & Marcusson, J. O. (2008) · European Neurology · doi:10.1159/000117341 · Cited by 64 · cited 11×
“, and Halliday, G. (2013). Can we clinically diagnose dementia with Lewy bodies yet? Transl. Neurodegener. 2, 4. doi: 10.1186/2047-9158-2-4 Iqbal, K., Alonso, A. D., Gondal, J. A., Gong, C. X., Haque, N., Khatoon, S., et al. (2000). Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.”
BackgroundInfluentialFrailty Among Alzheimer’s Disease Patients
Koch, G., Belli, L., Giudice, T. L., Lorenzo, F., Sancesario, G. M., Sorge, R. P., Bernardini, S., & Martorana, A. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312040010 · Cited by 54
Self-citationNeuropsychological Predictors of Rapidly Progressing Patients with Alzheimer’s Disease
Musicco, M., Salamone, G., Caltagirone, C., Cravello, L., Fadda, L., Lupo, F., Mosti, S., Perri, R., & Palmer, K. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000319533 · Cited by 50
Neuropathology of Parkinsonism in Patients with Pure Alzheimer's Disease
Horvath, J. E., Burkhard, P. R., Herrmann, F. R., Bouras, C., & Kövari, E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131289 · Cited by 49
Can we clinically diagnose dementia with Lewy bodies yet?
Huang, Y. M., & Halliday, G. M. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-4 · Cited by 49
Human striatum: the distribution of neurofibrillary tangles in Alzheimer's disease
Selden, N. R. W., Mesulam, M. M., & Geula, C. (1994) · Brain Research · doi:10.1016/0006-8993(94)91136-3 · Cited by 47
Brain dopamine D-2 receptors in senile dementia
Rinne, J. O., S�k�, E., Palj�rvi, L., et al. (1986) · Journal of Neural Transmission · doi:10.1007/bf01249611 · Cited by 43
Complexity of a human being: changes with age
Yates, F. E. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00261-5 · Cited by 30
Apathy Predicts More Severe Parkinsonism in Alzheimer's Disease
STARKSTEIN, S. E., Merello, M., Brockman, S., Bruce, D. G., Petracca, G., & Power, B. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31818a0e35 · Cited by 29
Clinical Symptoms and Symptom Signatures of Alzheimer's Disease Subgroups
Iqbal, K., Flory, M. J., & Soininen, H. S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130899 · Cited by 22
Cited by
Alzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Nobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacovazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14727 · Cited by 514
Social brain, social dysfunction and social withdrawal
Porcelli, S., Van Der Wee, N., van der Werff, S., Aghajani, M., Glennon, J. C., van Heukelum, S., Mogavero, F., Lobo, A., Olivera, F. J., Lobo, E., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.012 · Cited by 391
Management of oxidative stress and other pathologies in Alzheimer’s disease
Simunkova, M., Alwasel, S. H., Alhazza, I. M., Jomova, K., Kollar, V., Rusko, M., & Valko, M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02538-y · Cited by 303
Metadata
- Authors
- Martorana, A., & Koch, G.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-09-25
- Volume
- 6
- Pages
- 252-252
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W1606236576
- Cited by
- 275
- References
- 71
- FWCI
- 8.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.